Humacyte (HUMA) Scheduled to Post Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA) is scheduled to issue its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Price Performance

Shares of HUMA traded down $0.04 during trading hours on Thursday, hitting $5.39. 305,824 shares of the stock were exchanged, compared to its average volume of 2,336,031. The stock’s 50-day moving average price is $5.49 and its two-hundred day moving average price is $6.12. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The company has a market cap of $643.30 million, a price-to-earnings ratio of -4.31 and a beta of 1.47. Humacyte has a 12-month low of $2.08 and a 12-month high of $9.97.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the sale, the chief executive officer now directly owns 4,029,374 shares in the company, valued at $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Laura E. Niklason sold 157,704 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total transaction of $854,755.68. Following the sale, the chief executive officer now owns 3,519,558 shares of the company’s stock, valued at approximately $19,076,004.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the sale, the chief executive officer now directly owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,084,153 shares of company stock worth $6,869,996. Company insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

HUMA has been the subject of a number of recent research reports. HC Wainwright increased their target price on shares of Humacyte from $6.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. TD Cowen reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Thursday, October 10th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humacyte presently has a consensus rating of “Buy” and a consensus target price of $11.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.